Literature DB >> 23917453

Age at diagnosis may trump family history in driving BRCA testing in a population of breast cancer patients.

Hetal S Vig1, Anne Marie McCarthy, Kaijun Liao, Mirar Bristol Demeter, Tracey Fredericks, Katrina Armstrong.   

Abstract

BACKGROUND: Standard BRCA genetic testing criteria include young age of diagnosis, family history, and Jewish ancestry. The purpose of this study was to assess the effect of these criteria on BRCA test utilization in breast cancer patients.
METHODS: Breast cancer patients aged 18 to 64 years living in Pennsylvania in 2007 completed a survey on family history of breast and ovarian cancer and BRCA testing (N = 2,213). Multivariate logistic regression was used to estimate odds of BRCA testing by patient characteristics, and predicted probabilities of testing were calculated for several clinical scenarios.
RESULTS: Young age at diagnosis (<50 years) was strongly associated with BRCA testing, with women diagnosed before age 50 years having nearly five times the odds of receiving BRCA testing compared to women diagnosed at age 50 or older (OR = 4.81; 95% CI, 3.85-6.00; P < 0.001). Despite a similar BRCA mutation prevalence estimate (8-10%), a young Jewish patient <50 years with no family history had markedly higher predicted probability of testing (63%) compared with an older, non-Jewish breast cancer patient with more than one first-degree relative (43%).
CONCLUSION: Age at diagnosis, Jewish ancestry, and both maternal and paternal family history are strongly predictive of BRCA testing. However, among women diagnosed at age 50 or older, family history may be an underused criterion that may benefit from targeted intervention. IMPACT: Robust methods specific to ascertaining detailed family history, such as through electronic medical records, are needed to accurately identify patients for BRCA testing.

Entities:  

Mesh:

Year:  2013        PMID: 23917453      PMCID: PMC3799946          DOI: 10.1158/1055-9965.EPI-13-0426

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  Factors associated with decisions about clinical BRCA1/2 testing.

Authors:  K Armstrong; K Calzone; J Stopfer; G Fitzgerald; J Coyne; B Weber
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-11       Impact factor: 4.254

2.  Integration of family history and medical management of patients with hereditary cancers.

Authors:  S T Tinley; H T Lynch
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

3.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

Review 4.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

5.  Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.

Authors:  Katrina F Trivers; Laura-Mae Baldwin; Jacqueline W Miller; Barbara Matthews; C Holly A Andrilla; Denise M Lishner; Barbara A Goff
Journal:  Cancer       Date:  2011-07-25       Impact factor: 6.860

6.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network.

Authors:  C Julian-Reynier; H Sobol; C Sévilla; C Noguès; P Bourret
Journal:  Psychooncology       Date:  2000 Nov-Dec       Impact factor: 3.894

8.  Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.

Authors:  S U Dhar; H P Cooper; T Wang; B Parks; S A Staggs; S Hilsenbeck; S E Plon
Journal:  Breast Cancer Res Treat       Date:  2011-04-05       Impact factor: 4.872

9.  Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.

Authors:  Douglas E Levy; Judy E Garber; Alexandra E Shields
Journal:  J Gen Intern Med       Date:  2009-05-20       Impact factor: 5.128

10.  Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations.

Authors:  Esme Finlay; Jill E Stopfer; Eric Burlingame; Katherine Goldfeder Evans; Katherine L Nathanson; Barbara L Weber; Katrina Armstrong; Timothy R Rebbeck; Susan M Domchek
Journal:  Genet Test       Date:  2008-03
View more
  2 in total

1.  Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.

Authors:  Martin P Nilsson; Christof Winter; Ulf Kristoffersson; Martin Rehn; Christer Larsson; Lao H Saal; Niklas Loman
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

2.  Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake.

Authors:  Martin P Nilsson; Erik D Nilsson; Barbro Silfverberg; Åke Borg; Niklas Loman
Journal:  Genet Med       Date:  2018-06-06       Impact factor: 8.822

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.